Sun J.,Southern Medical UniversityGuangdong Province |
Ma H.,Capital Medical University |
Xie Q.,Shanghai JiaoTong University |
Xie Y.,Beijing DiTan Hospital |
And 16 more authors.
Journal of Hepatology | Year: 2016
Background & Aims Response-guided therapy has been confirmed to be an effective strategy for the treatment of chronic hepatitis C in the pegylated interferon (PegIFN) era, but no randomized trial utilizing this strategy has been conducted in chronic hepatitis B. Methods In this open-label, multicenter, randomized trial, HBeAg positive patients were treated with PegIFN (180 μg/week) for 24 weeks. Early responders (HBsAg <1500 IU/ml and HBV DNA <105 copies/ml at week 24) received PegIFN for a further 24 weeks (arm A), while non-early responders were randomized to PegIFN for another 24 weeks (arm B), another 72 weeks (arm C) or PegIFN for another 72 weeks plus adefovir for 36 weeks (arm D). The primary endpoint was the change of quantitative HBsAg from baseline to the end of follow-up (EOF). Results For non-early responders, 96-week PegIFN monotherapy did not lead to a greater reduction of HBsAg from baseline to EOF, compared with 48-week PegIFN (−0.71 vs. −0.67 log10 IU/ml, P = 0.407). The rate of HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF were similar for arms B, C and D (17.9%, 23.9% and 25.0% respectively). For patients with HBsAg <1500 IU/ml or HBV DNA <105 copies/ml at week 24, 38.4% and 37.0% achieved HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF respectively. Conclusions Patients with HBsAg <1500 IU/ml or HBV DNA <105 copies/ml at week 24 would benefit from continued PegIFN treatment. Extending the duration of PegIFN with or without adding adefovir did not show superiority over 48 weeks PegIFN monotherapy. Lay summary Extending the duration of pegylated interferon (PegIFN) alfa-2a is not recommended in HBeAg positive patients as treatment extension beyond 48 weeks did not show convincing benefit. Patients who achieved HBsAg <1500 IU/ml or HBV DNA <105 copies/ml after 24-week PegIFNα-2a showed satisfactory outcome after the withdrawal of finite PegIFNα-2a treatment. Clinical Trial Number: NCT01086085. © 2016 European Association for the Study of the Liver
Xiao L.,Southern Medical UniversityGuangdong Province |
Gao Y.,Southern Medical UniversityGuangdong Province |
Zhang L.,Southern Medical UniversityGuangdong Province |
Chen P.,Southern Medical UniversityGuangdong Province |
And 2 more authors.
Journal of Affective Disorders | Year: 2016
Background Previous literatures on quality of life (QoL) in bipolar disorder (BD) strongly suggested that a disease-specific QoL measure for patients with BD should be developed to evaluate QoL more specifically and reliably. To our knowledge, "Quality of Life in Bipolar Disorder" (QoL.BD) is the first and only questionnaire produced to specifically measure QoL in people with BD. In China, there is no disease-targeted measure available to specifically measure QoL in Chinese patients with BD. Objective The aim of the study is to revise and validate the brief version of the QoL.BD (Bref QoL.BD) into Chinese version. Methods All the items of the Bref QoL.BD was translated into Chinese language, using the Brislin translation mode. The questionnaire was administered to a total sample of 231 subjects, including 101 BD patients and 130 healthy controls, to test the psychometric properties of Bref QoL.BD (e.g. internal consistency, retest reliability, content validity, item analysis, confirmatory factor analysis, criterion validity, convergent validity, discriminative validity and feasibility). Results The Chinese version of the Bref QoL.BD had very high internal consistency (Cronbach's alpha=0.815) and retest reliability (intraclass correlation coefficient (ICC)=0.808). Confirmatory factor analysis (CFA) validated the original one-factor structure. The direction and magnitude of correlations with 36-item Short-Form Health Survey (SF-36; rs= 0.313, P<0.001) and 17-Hamilton Depression Rating Scale(HAMD; rs=-0.328, P <0.001) suggesting the criterion validity and convergent validity, respectively. The scores of Bref QoL.BD in subsyndromic BD group (HDRS≥4 and BRMS≥3), asymptomatic BD group (HDRS≤3 and BRMS≤2) and the control group significantly decreased successively, suggesting a discriminative validity of the instrument. Limitations Cross-sectional design and a small sample size from only one tertiary care center. And BD patients enrolled were euthymic, excluding the acute BD patients. Conclusions The Chinese version of the Bref QoL.BD is a feasible, reliable and valid tool for the assessment of QoL for Chinese BD patients. © 2016 Published by Elsevier B.V.
Chen P.L.,Southern Medical UniversityGuangdong Province |
Li W.T.,The Third Affiliated Hospital of Southern Medical UniversityGuangdong Province |
Wang J.,Southern Medical UniversityGuangdong Province |
Jiang Y.D.,Southern Medical UniversityGuangdong Province |
And 3 more authors.
Genetics and Molecular Research | Year: 2015
Genetic polymorphisms (C677T and A1298C) in methylenetetrahydrofolate reductase (MTHFR) were shown to be related to prostate cancer risk in previous studies; however, the results are controversial. We performed a meta-analysis of previous studies and quantitatively estimated these associations. Pubmed, Embase, and Cochrane Library Database were searched for published case-control studies evaluating the association between C677T (or A1298C) and prostate cancer risk. Pooled associations were presented as odds ratios (ORs) along with their 95% confidence intervals. Twenty-one case control studies were identified for meta-analysis that included 21,581 participants. No significant associations were found between the MTHFR polymorphisms C677T or A1298C and prostate cancer risk in our meta-analysis. However, in subgroup analyses, the C677T CT polymorphism was associated with increased prostate cancer risk in East Asians (CT vs CC+TT: OR = 1.324, P = 0.03). The A1298C CC polymorphism in MTHFR was also linked to slightly reduced prostate cancer risk in European residents (CC vs AC+AA: OR = 0.751, P = 0.004; CC vs AA: OR = 0.768, P = 0.011), whereas it was associated with a significantly increased prostate cancer risk in Asian residents (CC vs AA: OR = 1.862, P = 0.006). The C677T CT polymorphism of MTHFR may be a risk factor for prostate cancer in East Asians. The association between the MTHFR A1298C CC genotype and prostate cancer risk may vary within different populations. Large-scale well-designed studies are required to confirm these associations. © FUNPEC-RP.
Bi Y.-M.,Southern Medical UniversityGuangdong Province |
Xu J.-B.,Southern Medical UniversityGuangdong Province |
An H.-Y.,Southern Medical UniversityGuangdong Province
World Chinese Journal of Digestology | Year: 2014
MicroRNAs (miRNAs) are single-stranded, 18-24 nucleotide long, non-coding RNA molecules which are involved in virtually every cellular process including proliferation, differentiation and apoptosis by specifically interacting with the mRNA and regulating the expression of genes. Recently it has been found that miRNAs cooperate with transforming growth factor (TGF-β), nuclear factor kappa B (NF-κB), tumor necrosis factor α (TNF-α) and other cytokines, and form complex "network" signaling pathways to influence the activation, proliferation, migration and apoptosis of hepatic stellate cells (HSCs), suggesting that miRNAs may regulate biological behaviors of HSCs via various signal transduction pathways, and have a great influence on the development of hepatic fibrosis. This article will review the impact of miRNAs on the biological functions of HSCs via different signal transduction pathways. © 2014 Baishideng Publishing Group Inc. All rights reserved.